What do we know about bleeding risk in patients with cancer?
Venous thromboembolism (VTE) is a well-recognized complication in patients with cancer, with an increase in risk by a...
Therapy
DEBATE: Should VTE treatment continue beyond six months? The evidence behind the decision to continue anticoagulation
During the 11th ICTHIC, Agnes YY Lee and Marcello Di Nisio debated whether anticoagulation treatment should be...
DEBATE: Should VTE treatment continue beyond 6 months? Evidence supporting anticoagulation discontinuation
During the 11th ICTHIC, Agnes YY Lee and Marcello Di Nisio debated whether anticoagulation treatment should be...
Evolving data on cardiovascular complications in cancer
During the 11th ICTHIC, Hugo Ten Cate talked about the evolving data on cardiovascular complications in cancer. Here,...
Thrombosis management in hematological cancers vs solid tumors: what are the differences?
During the ICTHIC webinar “CAT management: challenges in different cancer populations,” Prof Darko Antic...
VTE risk in patients with ovarian cancer undergoing neoadjuvant chemotherapy.
Ovarian cancer is the ninth most common type of cancer and the seventh most common cause of cancer death in women . In...
Coagulation proteases, DOACs and their clinical impact on checkpoint inhibitor therapy
The hemostatic system in cancer The hemostatic system forms an integral part of the innate immune system and...
The treatment of CAT in the real-world setting: CAT treatment algorithm
During the ICTHIC webinar “Clinical insights in CAT to include COVID‐19“, Prof. Florian Langer gave a...
Multiple myeloma-associated VTE risk prediction. A talk report from the 10th ICTHIC
During the 10th ICTHIC, prof Kristen Sanfilippo (Assistant Professor at the Washington University School of Medicine in...
VTE in Palliative Care Patients: What do we know? A talk report from the 10th ICTHC
During the 10th ICTHIC, Professor Simon Noble (Cardiff University, UK) talked about the management of VTE in patients...